ASX-Dividend-Report-Banner

Archives

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30
Is Rithm Property Trust Facing Uncertainty In Real Estate Trends?
Real Estate

Is Rithm Property Trust Facing Uncertainty In Real Estate Trends?

Is Rithm Property Trust Facing Uncertainty in Real Estate Trends?

Stocks Tick Higher After Data on Job Openings, Consumer Confidence
Market Updates

Stocks Tick Higher After Data on Job Openings, Consumer Confidence

Stocks turned higher on Tuesday following mixed updates on consumer confidence and the labor market. The Dow rose 231 points, or 0.6%. The S&P 500 was up 0.3%. The Nasdaq Composite gained 0.3%. The Do...

  • April 29, 2025 07:18 AM PDT
  • EODHD
Kytopen and Aldevron Expedite Cell Therapy Manufacturing Through Their Collaborative CRISPR-mediated Cellular Engineering Workflow
Market Updates

Kytopen and Aldevron Expedite Cell Therapy Manufacturing Through Their Collaborative CRISPR-mediated Cellular Engineering Workflow

Kytopen and Aldevron announce collaboration to expedite cell therapy manufacturing by combining their novel technologies. High transgene expression and improved safety profile of Aldveron's Nanoplasmi...

  • April 29, 2025 07:07 AM PDT
  • EODHD
American Airlines is suing JetBlue after a partnership fell apart
Market Updates

American Airlines is suing JetBlue after a partnership fell apart

Photo: Mario Tama (Getty Images) American Airlines (AAL) and JetBlue (JBLU) had been partners. Now they’ll be seeing one another in court. From 2020 through 2024, the two airlines partnered on flights...

  • April 29, 2025 07:01 AM PDT
  • EODHD
Affimed Shows Higher Exposure of AFM24 is Associated with Significantly Higher Response Rates and Progression-Free Survival in Refractory NSCLC Patients at AACR Annual Meeting
Market Updates

Affimed Shows Higher Exposure of AFM24 is Associated with Significantly Higher Response Rates and Progression-Free Survival in Refractory NSCLC Patients at AACR Annual Meeting

An exposure-outcome analysis in 72 patients with refractory non-small cell lung cancer (NSCLC) who received AFM24 at 480 mg weekly demonstrates that higher drug exposure (above median) leads to improv...

  • April 29, 2025 07:00 AM PDT
  • EODHD
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.